Varicella-Zoster Virus–Specific Antibody Responses in 50–59-Year-Old Recipients of Zoster Vaccine | Zendy

Myron J. Levin | Zendy; Kenneth E. Schmader | Zendy; John W. Gnann | Zendy; Shelly McNeil | Zendy; Timo Vesikari | Zendy; Robert F. Betts | Zendy; Susan Keay | Zendy; Jon E. Stek | Zendy; Nickoya D. Bundick | Zendy; ShuChih Su | Zendy; Yanli Zhao | Zendy; Xiaoming Li | Zendy; Ivan S. F. Chan | Zendy; Paula W. Annunziato | Zendy; Janie Parrino | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Varicella-Zoster Virus–Specific Antibody Responses in 50–59-Year-Old Recipients of Zoster Vaccine

Author(s) -

Myron J. Levin,

Kenneth E. Schmader,

John W. Gnann,

Shelly McNeil,

Timo Vesikari,

Robert F. Betts,

Susan Keay,

Jon E. Stek,

Nickoya D. Bundick,

ShuChih Su,

Yanli Zhao,

Xiaoming Li,

Ivan S. F. Chan,

Paula W. Annunziato,

Janie Parrino

Publication year - 2013

Publication title -

the journal of infectious diseases

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.69

H-Index - 252

eISSN - 1537-6613

pISSN - 0022-1899

DOI - 10.1093/infdis/jit342

Subject(s) - medicine , varicella zoster virus , immunogenicity , vaccination , titer , virology , virus , placebo , antibody , immunology , antibody response , seroconversion , alternative medicine , pathology

Prevaccination and 6-week postvaccination samples from the immunogenicity substudy (n = 2269) of the zoster vaccine (ZV) efficacy trial (N = 22 439) in 50-59-year-old subjects were examined for varicella-zoster virus-specific antibody responses to vaccination. The varicella-zoster virus geometric mean titer (GMT) and geometric mean fold rise were higher in ZV recipients than in placebo recipients (GMT, 660.0 vs 293.1 glycoprotein enzyme-linked immunosorbent assay units/mL [P < .001], respectively; geometric mean fold rise, 2.31 vs 1.00 [P < .025]). In each group there was a strong inverse correlation between postvaccination GMT and risk of subsequent herpes zoster. Although these data provide strong evidence that relates ZV-induced antibody and the risk of herpes zoster, a protective threshold was not determined. Clinical Trials Registration. NCT00534248.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research